AbbVie Posts More Positive Hep-C Results, ENTA Jumps
Insights - Last month, AbbVie (ABBV) reported that its new Hepatitis-C treatment was effective in 96% of patients who had never been treated for the virus. On … Continue Reading
Read nowSearch Results for enanta
Our Top Stories In Healthcare This Week
Recap - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read nowEveryone’s Piling Back Into Equities: Here’s Where PropThink is Involved
Long Ideas - Tekmira Pharmaceuticals (TKMR) announced a secondary offering on Wednesday and priced the deal before Thursday’s open. Tekmira is selling 3,750,000 common stock at a price … Continue Reading
Read nowBreakout Gains from These Late-Blooming Trades
Most Popular - For those that missed our press release on Friday, PropThink will be hosting a live interview and Q&A with Dr. Mark Murray, CEO of Tekmira Pharmaceuticals (TKMR) (TKM.TO) on Thursday, October 3 … Continue Reading
Read nowLocking in the Profits as PropThink Wraps Up Another Week
Most Popular - Enanta Pharmaceuticals (ENTA) IPO’d in March but remains virtually flat following an initial spike in share price. In our view, the stock is quite cheap … Continue Reading
Read now